Recently the investigation of the immune responses to Human papillomavirus(HPV) infection has been employed to identify serological markers that are associated with anogenital malignancies and/or disease progression. We investigated serological
responses in sera from Korean women with or without a history of cervical carcinoma. We used bacterially derived trpE fusion proteins as antigens for Western blot assays. Among women with cancer, 16/32(50%) and 20/32(63%) were positive for
antibodies to
at leat one of gene products of HPV 16 in the sera of cervical cancer patients were 47%(15/32;E4), 19%)(6/32: E6), 38%(12/32; E7), 22%(7/32; L1), and 6%(2/32; L2), respectively, while none for E4, e6 and L2, 2/20 for E7(10%), and 1/20 for 1(5%)
among
the cancer-free individuals.
The detection rate of antibodies to the HPV 16 appeared to be higher in the cervical carcinomas, implying the correlation between HPV 16 and cervical carcinoma, although the stastical significance of this interpretation should wait for the
analysis
of
more cases.
|